Close
Close
Treatment News

More Than 25 Data Presentations from Sanofi Genzyme’s Multiple Sclerosis Franchise to Be Featured at AAN

1.5
1.5 from 2 votes
Friday, April 20, 2018

CAMBRIDGE, Mass. - New investigational data on Sanofi Genzyme's marketed treatments for relapsing multiple sclerosis (MS), Lemtrada (alemtuzumab) and Aubagio (teriflunomide), will be presented at the 70th annual meeting of the American Academy of Neurology (AAN).

"The new data being presented at AAN continue to expand the body of knowledge on the use of Aubagio and Lemtrada, in both the clinical and real-world settings," said Tom Snow, Sanofi Genzyme's Global Head of Multiple Sclerosis. "As part of our long-term commitment to the MS community, we remain dedicated to finding new ways to improve patient care, with a focus on ongoing research into our current products as well as potential new treatment options."

AAN is taking place April 21-27, 2018 in Los Angeles, California. Data presentations are as follows. All abstracts are available on the AAN website.

Sunday, April 22, 2018

        Platform Session S8 (3:30 – 5:30 p.m.)

  • Long-term Outcomes in Patients with Progressive Forms of Relapsing MS Treated with Teriflunomide: Real-World Evidence (Platform #003; 4:06pm)

    Poster Session P1 (4:00 – 5:30 p.m.)

 

  • Comparative Effectiveness of Teriflunomide and Dimethyl Fumarate in Patients With Relapsing Forms of MS in the Real-World Teri-RADAR Study (Poster #355)
  • Treatment Experiences of Patients with MS: Results From the Global vs.MS Survey (Poster #381)

Wednesday, April 25, 2018

Platform Session S36 (3:30 – 5:30 p.m.)

  • Alemtuzumab-Treated Patients Experienced Decreased MRI Disease Activity and Slowing of Brain Volume Loss Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS I (TOPAZ Study) (Platform #003; 3:54 p.m.)


Poster Session P4 (5:30 – 7:00 p.m.)

  • Evaluation of Teriflunomide in Children and Adolescents With Relapsing MS: TERIKIDS Phase 3 Study Design, Enrollment Update, and Baseline Data (Poster #354)
  • Pregnancy Outcomes in Patients With MS Treated With Teriflunomide: Clinical Study and Postmarketing Data (Poster #361)
  • Teriflunomide (Aubagio ) International Pregnancy Registry: Enrollment Update (Poster #371)

Thursday, April 26, 2018

Poster Session P5 (5:30 – 7:00 p.m.)

  • Alemtuzumab Reduced MRI Lesions and the Rate of Brain Volume Loss in CARE-MS II Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (Poster #031; will also be presented orally at 12:05 p.m.)
  • Limited Impact of Long-term Teriflunomide Treatment on Lymphocyte Counts and Infection Rates in the Pooled TEMSO and TOWER Core and Extension Trials (Poster #357)
  • Lymphocyte Counts in Patients Treated With Teriflunomide: Observations From Phase 3 Clinical Trials and the Real-World Teri-PRO Study (Poster #376)

Friday, April 27, 2018 – Poster Session P6 (4:00 – 5:30 p.m.)

Lemtrada

  • Efficacy and Safety of Alemtuzumab in Real World Italian Patients Switching from Natalizumab (Poster #357)
  • Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS I Extension (Poster #362)
  • Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension (Poster #363)
  • Disability Improvement Is Observed in Each Functional System in Alemtuzumab-Treated Patients With Active RRMS: Results From CARE-MS II Extension (Poster #364)
  • Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (Poster #366)
  • Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (Poster #367)
  • Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (Poster #368)
  • Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (Poster #369)
  • Durable Reduction in MRI Disease Activity and Slowing of Brain Volume Loss in Alemtuzumab-Treated Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (Poster #375)
  • Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (Poster #376)
  • Alemtuzumab Improves Patient-reported Quality of Life Outcomes in Patients With Relapsing-remitting Multiple Sclerosis: Results From the CARE-MS I Extension Study (Poster #380)
  • Alemtuzumab Improves Patient-reported Quality of Life Outcomes in Patients With Rapidly Evolving Severe Relapsing-remitting MS: Results From the CARE-MS I Extension Study (Poster #392)

Aubagio

  • Evaluation of the Long-term Treatment Effect of Teriflunomide on Cognitive Outcomes and Association With Brain Volume Change: Data From TEMSO and its Extension Study (Poster #372)
  • Long-term Disability Outcomes in Teriflunomide-Treated Patients in TEMSO and TOWER: An Analysis Utilizing the Topographical Model of MS (Poster #374)
  • Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension Study (Poster #389)
  • Long-term Efficacy and Safety Outcomes of Teriflunomide Treatment in TEMSO and TOWER (Poster #391)
  • Treatment Satisfaction With Teriflunomide in Patients Switching From a Prior Disease-Modifying Therapy: Results From the Phase 3 TENERE and Phase 4 Teri-PRO Clinical Trials (Poster #396)

About Lemtrada (alemtuzumab)
Lemtrada is approved in more than 60 countries, with additional marketing applications under review by regulatory authorities globally. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients worldwide and 5,400 patient-years of follow-up. More than 19,0001 patients have been treated with Lemtrada commercially worldwide.

Sanofi Genzyme holds the worldwide rights to alemtuzumab and has responsibility for its development and commercialization in multiple sclerosis. Bayer Healthcare receives contingent payments based on global sales revenue.

About Aubagio (teriflunomide)
Aubagio is approved in more than 70 countries, with additional marketing applications under review by regulatory authorities globally. Aubagio is supported by one of the largest clinical programs of any MS therapy, with more than 5,000 trial participants in 36 countries. More than 85,0001 patients are currently being treated with Aubagio commercially worldwide.

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more at www.sanofigenzyme.com.

Contacts:
Sanofi Genzyme Communications Contact
Erin Pascal, +1 617-685-5068
erin.pascal@sanofi.com

Source: Sanofi Genzyme
1.5
1.5 from 2 votes
Free Newsletter
Trending News
Videos
by Abidemi Uruejoma
6 views
by Abidemi Uruejoma
59 views
by Abidemi Uruejoma
57 views